United States Department of Veterans Affairs
VA National HIV/AIDS Website

HIV Meds Quarterly, Winter 2009

for Health Care Providers

HIV Meds Quarterly

Research Briefs

Fast Takes

  • Maraviroc
    In November 2008, maraviroc, the CCR5 antagonist, was granted traditional approval by the United States Food and Drug Administration (FDA). It had been given accelerated approval in 2007. It is intended for treatment-experienced patients with CCR5-tropic HIV infection.
    more on maravirocLink will take you outside the VA website. VA is not responsible for the content of the linked site.

  • Abacavir: Pediatric formulation
    The FDA recently approved a 300 mg scored tablet formulation of abacavir intended for pediatric patients. As with the previously available oral solution, abacavir is approved for children at least 3 months of age. The recommended dosage is 8 mg/kg BID (maximum dosage 300 mg BID). For patients who are ≥14 kg in weight and are able to take pills, the recommended dosage for the abacavir 300 mg scored tablet formulation is as follows:

    WeightPediatric Abacavir Dosage
    Wt 14-21 kg150 mg (1/2 tablet) BID
    Wt >21 kg to <30 kg150 mg Q AM (1/2 tablet) + 300 mg (1 tablet) Q PM
    Wt ≥30 kg300 mg (1 tablet) BID

    more on abacavirLink will take you outside the VA website. VA is not responsible for the content of the linked site.

  • Abacavir/lamivudine: DHHS recommendations
    The November 2008 U.S. DHHS adult and adolescent ARV guidelines designate abacavir/lamivudine as an "Alternative" NRTI combination for use in initial therapy. The decision to downgrade abacavir/lamivudine (Epzicom) was based on recent study findings of potential cardiovascular risk associated with abacavir, and of inferior efficacy when abacavir/lamivudine (as opposed to tenofovir/emtricitabine) was used in patients with pretreatment HIV RNA levels >100,000 copies/mL (patients also received efavirenz or atazanavir/ritonavir). See the Fall 2008 and Summer 2008 installments of HIV Meds Quarterly for further information.
    more on abacavirLink will take you outside the VA website. VA is not responsible for the content of the linked site., more on lamivudineLink will take you outside the VA website. VA is not responsible for the content of the linked site.

Reference